Skip to main content
Premium Trial:

Request an Annual Quote

Definiens Places New Tissue Array Analysis Platform at Karmanos Cancer Institute


By Justin Petrone

Definiens this week announced that scientists at the Barbara Ann Karmanos Cancer Institute in Detroit will use its tissue microarray image analysis software in their cancer-diagnosis and biomarker-development projects.

The Karmanos Cancer Institute will use Definiens' Tissue Studio 2.0 digital pathology software to automate tissue section and microarray analysis. Researchers at the institute "aim to improve the speed and accuracy of diagnosis by automating image analysis of tissue sections stained for morphology and biomarker expression, as well as tissue microarrays measuring clinically relevant biomarkers," according to Munich-based Definiens.

Thomas Colarusso, vice president of Definiens' North American sales and operations, told BioArray News that the newly launched software provides "full tissue microarray support, for both bright field and immunofluorescent images, and supports metadata import on a per-core basis."

He said that Definiens' software can be used to "look for correlations between biomarker expression, tumor morphology, and clinical endpoints of interest."

Gerold Bepler, president and CEO of the Karmanos Institute, said in a statement that the institute will use Tissue Studio to analyze cancers, including lung, breast, and pancreatic cancer, on the cellular and sub-cellular level.

"Automating image analysis in our research will significantly enhance our ability to apply knowledge of cancer characteristics to patient diagnosis and treatment," Bepler said. "The software will help us classify tumors and generate better prognostic and predictive data. We expect this will improve our ability to stratify patients for the most promising clinical approach."

Financial terms of the deal were not discussed.